Literature DB >> 31464029

Sema3E is required for migration of cranial neural crest cells in zebrafish: Implications for the pathogenesis of CHARGE syndrome.

Zhi-Zhi Liu1,2,3, Jingjing Guo4, Yanli Lu5, Wenfeng Liu1, Xiaofeng Fu1, Tianbing Yao1, Yanjun Zhou1, Hong A Xu1,2,3.   

Abstract

CHARGE syndrome is a congenital disorder with multiple malformations in the craniofacial structures, and cardiovascular and genital systems, which are mainly affected by neural crest defects caused by loss-of-function mutations within chromodomain helicase DNA-binding protein 7 (CHD7). However, many patients with CHARGE syndrome test negative for CHD7. Semaphorin 3E (sema3E) is a gene reported to be mutated in patients with CHARGE syndrome. However, its role in the pathogenesis of CHARGE syndrome has not been verified experimentally. Here, we report that the knockdown of sema3E results in severe craniofacial malformations, including small eyes, defective cartilage and an abnormal number of otoliths in zebrafish embryos, which resemble the major features of CHARGE syndrome. Further analysis reveals that the migratory cranial neural crest cells are scattered in the region of the hindbrain, and the postmigratory neural crest cells are reduced in the pharyngeal arches upon sema3E knockdown. Notably, immunostaining and time-lapse imaging analyses of a neural crest cell-labelled transgenic fish line, sox10:EGFP, show that the migration of cranial neural crest cells is severely impaired, and many of these cells are misrouted upon sema3E knockdown. Furthermore, the sox10-expressing cranial neural crest cells are scattered in chd7 homozygous mutants, which phenocopied the phenotype in sema3E morphants. Overexpression of sema3E rescues the phenotype of scattered cranial neural crest cells in chd7 homozygotes, indicating that chd7 may control the expression of sema3E to regulate cranial neural crest cell migration. Collectively, our data demonstrate that sema3E is involved in the pathogenesis of CHARGE syndrome by modulating cranial neural crest cell migration.
© 2019 The Authors. International Journal of Experimental Pathology © 2019 International Journal of Experimental Pathology.

Entities:  

Keywords:  CHARGE syndrome; Chd7; cranial neural crest cells; migration; semaphorin 3E

Mesh:

Substances:

Year:  2019        PMID: 31464029      PMCID: PMC6877996          DOI: 10.1111/iep.12331

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  30 in total

1.  The calmodulin-stimulated adenylate cyclase ADCY8 sets the sensitivity of zebrafish retinal axons to midline repellents and is required for normal midline crossing.

Authors:  Hong Xu; Sarah G Leinwand; Alison L Dell; Emma Fried-Cassorla; Jonathan A Raper
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

2.  Dysregulation of cotranscriptional alternative splicing underlies CHARGE syndrome.

Authors:  Catherine Bélanger; Félix-Antoine Bérubé-Simard; Elizabeth Leduc; Guillaume Bernas; Philippe M Campeau; Seema R Lalani; Donna M Martin; Stephanie Bielas; Amanda Moccia; Anshika Srivastava; David W Silversides; Nicolas Pilon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

3.  Semaphorin 3d promotes cell proliferation and neural crest cell development downstream of TCF in the zebrafish hindbrain.

Authors:  Jason D Berndt; Mary C Halloran
Journal:  Development       Date:  2006-09-13       Impact factor: 6.868

4.  Dynamic control of β1 integrin adhesion by the plexinD1-sema3E axis.

Authors:  Young I Choi; Jonathan S Duke-Cohan; Wei Chen; Baoyu Liu; Jérémie Rossy; Thibault Tabarin; Lining Ju; Jingang Gui; Katharina Gaus; Cheng Zhu; Ellis L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-16       Impact factor: 11.205

Review 5.  CHARGEd with neural crest defects.

Authors:  Silke Pauli; Ruchi Bajpai; Annette Borchers
Journal:  Am J Med Genet C Semin Med Genet       Date:  2017-10-30       Impact factor: 3.908

6.  CHARGE Syndrome.

Authors:  Alexandra Hudson; Carrie-Lee Trider; Kim Blake
Journal:  Pediatr Rev       Date:  2017-01

7.  Response to correspondence to Hale et al. atypical phenotypes associated with pathogenic CHD7 variants and a proposal for broadening CHARGE syndrome clinical diagnostic criteria.

Authors:  Caitlin L Hale; Adrienne N Niederriter; Glenn E Green; Donna M Martin
Journal:  Am J Med Genet A       Date:  2016-03-21       Impact factor: 2.802

8.  cAMP-induced expression of neuropilin1 promotes retinal axon crossing in the zebrafish optic chiasm.

Authors:  Alison L Dell; Emma Fried-Cassorla; Hong Xu; Jonathan A Raper
Journal:  J Neurosci       Date:  2013-07-03       Impact factor: 6.167

9.  CHD7 cooperates with PBAF to control multipotent neural crest formation.

Authors:  Ruchi Bajpai; Denise A Chen; Alvaro Rada-Iglesias; Junmei Zhang; Yiqin Xiong; Jill Helms; Ching-Pin Chang; Yingming Zhao; Tomek Swigut; Joanna Wysocka
Journal:  Nature       Date:  2010-02-03       Impact factor: 49.962

10.  CHD7, the gene mutated in CHARGE syndrome, regulates genes involved in neural crest cell guidance.

Authors:  Yvonne Schulz; Peter Wehner; Lennart Opitz; Gabriela Salinas-Riester; Ernie M H F Bongers; Conny M A van Ravenswaaij-Arts; Josephine Wincent; Jacqueline Schoumans; Jürgen Kohlhase; Annette Borchers; Silke Pauli
Journal:  Hum Genet       Date:  2014-04-13       Impact factor: 4.132

View more
  8 in total

1.  Sema3E is required for migration of cranial neural crest cells in zebrafish: Implications for the pathogenesis of CHARGE syndrome.

Authors:  Zhi-Zhi Liu; Jingjing Guo; Yanli Lu; Wenfeng Liu; Xiaofeng Fu; Tianbing Yao; Yanjun Zhou; Hong A Xu
Journal:  Int J Exp Pathol       Date:  2019-08-28       Impact factor: 1.925

2.  A Novel Loss-of-Function SEMA3E Mutation in a Patient with Severe Intellectual Disability and Cognitive Regression.

Authors:  Alyssa J J Paganoni; Federica Amoruso; Javier Porta Pelayo; Beatriz Calleja-Pérez; Valeria Vezzoli; Paolo Duminuco; Alessia Caramello; Roberto Oleari; Alberto Fernández-Jaén; Anna Cariboni
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

3.  Identification of a novel heterozygous missense mutation of SEMA3E (c.1327G>A; p. Ala443Thr) in a labor induced fetus with CHARGE syndrome.

Authors:  Xiao Song; Xueyan Wang; Li Ding; Dan He; Jin Sun; Na Xi; Yan Yin; Hui Peng; Lingling Sun
Journal:  Mol Genet Genomic Med       Date:  2019-11-06       Impact factor: 2.183

Review 4.  Semaphorin Regulation by the Chromatin Remodeler CHD7: An Emerging Genetic Interaction Shaping Neural Cells and Neural Crest in Development and Cancer.

Authors:  Antonella Lettieri; Roberto Oleari; Alyssa J J Paganoni; Cristina Gervasini; Valentina Massa; Alessandro Fantin; Anna Cariboni
Journal:  Front Cell Dev Biol       Date:  2021-04-01

5.  Partial CHARGE syndrome with bilateral retinochoroidal colobomas associated with 7q11.23 duplication syndrome: case report.

Authors:  Patrick L Donabedian; Jessica Y Walia; Swati Agarwal-Sinha
Journal:  BMC Ophthalmol       Date:  2022-03-04       Impact factor: 2.209

6.  Morphometric and Genetic Description of Trophic Adaptations in Cichlid Fishes.

Authors:  Leah DeLorenzo; Victoria DeBrock; Aldo Carmona Baez; Patrick J Ciccotto; Erin N Peterson; Clare Stull; Natalie B Roberts; Reade B Roberts; Kara E Powder
Journal:  Biology (Basel)       Date:  2022-08-03

Review 7.  Congenital heart defects in CHARGE: The molecular role of CHD7 and effects on cardiac phenotype and clinical outcomes.

Authors:  Joshua K Meisner; Donna M Martin
Journal:  Am J Med Genet C Semin Med Genet       Date:  2019-12-13       Impact factor: 3.359

8.  AKT Signaling Modifies the Balance between Cell Proliferation and Migration in Neural Crest Cells from Patients Affected with Bosma Arhinia and Microphthalmia Syndrome.

Authors:  Camille Laberthonnière; Elva Maria Novoa-Del-Toro; Raphaël Chevalier; Natacha Broucqsault; Vanitha Venkoba Rao; Jean Philippe Trani; Karine Nguyen; Shifeng Xue; Bruno Reversade; Jérôme D Robin; Anais Baudot; Frédérique Magdinier
Journal:  Biomedicines       Date:  2021-06-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.